
Arrowhead Pharmaceuticals, Inc.: updates and filings
Price
$43.65
November 19, 2026Market cap $6.2B
What Ploutos Investor adds for Arrowhead Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from FY2011
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
February 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 12, 2026Annual reportfor the period to Sep 30, 2026Form10-K
- Nov 12, 2026Results of operationsForm8-K
- Nov 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 4, 2026Material agreement entered, new material financial obligationForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 4, 2026Results of operationsForm8-K
- Aug 4, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 31, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 16, 2026Officer or director changeForm8-K
- May 19, 2026Filing (amendment)Form144/A
- May 19, 2026Filing (amendment)Form144/A
- May 19, 2026Filing (amendment)Form144/A
- May 7, 2026Shares registered for employeesFormS-8
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 7, 2026Results of operationsForm8-K
- May 6, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 28, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 24, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 20, 2026Shareholder voteForm8-K
- Feb 5, 2026Quarterly reportfor the period to Dec 31, 2025Form10-Q
- Feb 5, 2026Results of operationsForm8-K
- Jan 27, 2026Annual report to shareholdersfor the period to Jan 26, 2026FormARS
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 12, 2026 | 10-K | Annual reportfor the period to Sep 30, 2026 | Document |
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Nov 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 4, 2026 | 8-K | Material agreement entered, new material financial obligation | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 4, 2026 | 8-K | Results of operations | Document |
| Aug 4, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 31, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 16, 2026 | 8-K | Officer or director change | Document |
| May 19, 2026 | 144/A | Filing (amendment) | Document |
| May 19, 2026 | 144/A | Filing (amendment) | Document |
| May 19, 2026 | 144/A | Filing (amendment) | Document |
| May 7, 2026 | S-8 | Shares registered for employees | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| May 6, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 28, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 24, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 20, 2026 | 8-K | Shareholder vote | Document |
| Feb 5, 2026 | 10-Q | Quarterly reportfor the period to Dec 31, 2025 | Document |
| Feb 5, 2026 | 8-K | Results of operations | Document |
| Jan 27, 2026 | ARS | Annual report to shareholdersfor the period to Jan 26, 2026 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 2, 1998. Of its note and share prospectuses (424B, FWP), the newest 40 of 44.
The full analysis
What do Arrowhead Pharmaceuticals's filings show?
The filings are where every one of Arrowhead Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.